Novel Drug Shows Promising Efficacy for Patients With Multiple Myeloma


Cellular process

Results of an international clinical trial show potential for a novel drug to benefit patients with multiple myeloma whose disease recurred or was resistant to three or more earlier lines of treatment. “The MajesTEC-1 study update suggests patients with relapsed or refractory multiple myeloma receiving teclistamab achieved a deep response that was also durable,” says the study’s PI at Winship, Ajay K. Nooka, MD, MPH, a Georgia CTSA investigator.

Read More

Share This Story